Tesamorelin

Tesamorelin — Research Compound

Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) that specifically incorporates a trans-3-hexenoic acid group to increase its stability and potency. It is primarily studied for its ability to stimulate the pituitary gland to produce and secrete endogenous growth hormone. Researchers investigate Tesamorelin for its selective impact on visceral adipose tissue and its role in modulating lipid metabolism and insulin-like growth factor 1 (IGF-1) levels in specific metabolic research models.

Findings from early-stage clinical trials have reported:

• Significant reductions in visceral adipose tissue (VAT) of approximately 15–20% observed in clinical cohorts
  
• Sustained elevations in circulating IGF-1 levels reported throughout the study period
  
• Improvements in lipid profiles, including reductions in non-HDL cholesterol, noted in experimental models
  
• Observed preservation of lean body mass and stable glycemic control reported in research subjects
  

Researchers study Tesamorelin to explore the mechanisms of fat distribution and the regulation of the somatotropic axis. Its high specificity for abdominal fat reduction makes it a valuable tool for investigating metabolic syndrome and the biological drivers of lipodystrophy. By analyzing its effect on the GHRH receptor, researchers aim to better understand the systemic impact of optimized growth hormone secretion on cardiometabolic health.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use